pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The December 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are:
- Five new drug products have initiated pCPA negotiations, for a total of 36 active negotiations;
- Eight negotiations have been completed/closed, for a total of 196 joint completed/closed negotiations; and
- One new drug product was added to the “No pCPA Negotiations” list, for a total of 57 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level.
In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since November 30, 2017 is:
- Two new drug products have received recent CDEC or pERC recommendations, for a total of approximately 20 products under pCPA Consideration
Please see below for more details.
Negotiation Initiation
Five new drug products have initiated pCPA negotiations since the last update, for a total of 36 active negotiations
| Brand Name | Generic Name | Manufacturer | Indication | Recommendation/ Notification to Implement Date |
Time to Negotiation* (days) |
|---|---|---|---|---|---|
| Blincyto | blinatumomab | Amgen Canada | Adult Acute Lymphoblastic Leukemia (ALL) | September 18. 2017 | 88 days |
| Blincyto | blinatumomab | Amgen Canada | Pediatric Acute Lymphoblastic Leukemia | September 8, 2017 | 98 days |
| Caprelsa** | vandetanib | Sanofi Genzyme | Medullary Thyroid Cancer | April 17, 2017 | 242 days |
| Lancora | Ivabradine | Servier Canada Inc. | Heart failure, NYHA class II or III | May 24, 2017 | 205 days |
| Ocaliva | Obeticholic acid | Intercept Pharma Canada Inc. | Primary biliary cholangitis | July 25, 2017 | 143 days |
*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
** Note: This is the second negotiation for Caprelsa, the first was closed in August 2017
Negotiations Completed
- Eight negotiations have been completed/closed since the last update, for a total of 196 joint completed/closed negotiations.
- Eight negotiations were completed:
| Brand Name | Generic Name | Manufacturer | Indication | Negotiation Initiation | Duration * (days) |
|---|---|---|---|---|---|
| Cosentyx | secukinumab | Novartis Pharmaceuticals Canada Inc, | Psoriatic Arthritis | April, 2017 | 244 days |
| Cosentyx | secukinumab | Novartis Pharmaceuticals Canada Inc, | Ankylosing Spondylitis | April, 2017 | 244 days |
| Ibrance | palbociclib | Pfizer Canada Inc. | Advanced Breast Cancer | May, 2017 | 214 days |
| Kyprolis | carfilzomib | Amgen Canada Inc. | Multiple Myeloma | October, 2016 | 426 days |
| Kyprolis | carfilzomib | Amgen Canada Inc. | Multiple Myeloma (relapsed) | June, 2017 | 183 days |
| Ravicti | Glycerol phenylbutyrate | Horizon Therapeutics Canada/Horizon Pharma Ireland Ltd | Urea cycle disorders | April, 2017 | 244 days |
| Taltz | Ixekizumab | Eli Lilly Canada Inc. | Moderate to severe plaque psoriasis | May, 2017 | 214 days |
| Uptravi | Selexipag | Actelion Pharmaceuticals Canada Inc. | Pulmonary arterial hypertension | April, 2017 | 244 days |
- No negotiations were closed.
No pCPA Negotiation
- One new drug product was added to the “No pCPA Negotiations” list, for a total of 57 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level
| Brand Name | Generic Name | Manufacturer | Indication | Recommendation/ Notification to Implement Date |
CADTH Recommendation | Time to decision* (days) |
|---|---|---|---|---|---|---|
| Rituxan | Rituximab | Hoffman-La Roche Limited | Acute lymphoblastic leukemia | September 18, 2017 | Does not Recommend | 88 days |
*Approximation: decision date assumed to be mid-month for the purposes of the calculation
Based on information collected by MORSE Consulting:
- Two new drug products received a CDEC or pERC recommendation or notification to implement since the last update, for a total of approximately 20 products under pCPA Consideration.
| Brand Name | Generic Name | Manufacturer | Indication | Final Recommendation/Notification to Implement |
|---|---|---|---|---|
| Opdivo & Yervoy in combo | Nivolumab & ipilimumab | Bristol Myers Squibb Canada | Metastatic Melanoma | Conditional Reimbursement |
| Spinraza | Nusinersen | Biogen Canada Inc. | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions |
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
